Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
-
- Wolfgang P. Fendler
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
-
- Svenja Reinhardt
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
-
- Harun Ilhan
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
-
- Andreas Delker
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
-
- Guido Böning
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
-
- Franz J. Gildehaus
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
-
- Christian Stief
- Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany
-
- Peter Bartenstein
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
-
- Christian Gratzke
- Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany
-
- Sebastian Lehner
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
-
- Axel Rominger
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
収録刊行物
-
- Oncotarget
-
Oncotarget 8 (2), 3581-3590, 2016-09-24
Impact Journals, LLC
